• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Thursday, November 19, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Trump’s Deal Turns Sour as Voters Withdraw Support

    Trump’s Deal Turns Sour as Voters Withdraw Support

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Trump’s Deal Turns Sour as Voters Withdraw Support

    Trump’s Deal Turns Sour as Voters Withdraw Support

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home Science

Veterans and Lawmakers Lobby for Approval of MDMA Therapy

by Theinsightpost
August 8, 2024
in Science
0 0
0
Veterans and Lawmakers Lobby for Approval of MDMA Therapy

More than a half century after federal regulators banned most psychedelic compounds, the Food and Drug Administration is nearing a decision on a novel treatment for post-traumatic stress disorder that pairs talk therapy with MDMA, the club drug commonly known as Ecstasy or Molly.

The decision, which is expected in the coming days, has generated a groundswell of lobbying by veterans groups, researchers and members of Congress from both parties. Eighty lawmakers signed letters to the Biden administration this week, urging the F.D.A. to approve the application by the drug company Lykos Therapeutics.

The campaign was prompted in part by an expert panel’s unanimous rejection in June of Lykos’s application, because of what participants said were flaws in the company’s clinical trials and insufficient data.

“We have a mental health crisis and a suicide epidemic, with thousands of military veterans taking their own lives every year,” said Representative Jack Bergman, Republican of Michigan and a former Marine Corps general who helped organize the letter’s 60 backers in the House. “I would just ask the F.D.A. to consider the negative ramifications of them not taking action, which means more veterans will die needlessly.”

The lobbying campaign, unusual for a prospective new drug, underscores the high stakes and intense emotions surrounding psychedelic medicine, a field that has been growing in recent years as the country’s top universities race one another to establish psychedelic research institutes.

The passions — and the millions of dollars in private investment flooding the field — have been buoyed by a growing body of data suggesting that compounds like LSD, psilocybin mushrooms and MDMA can have significant therapeutic effects on hard-to-treat mental health conditions like depression, anxiety and obsessive compulsive disorder. The federally prohibited substances are listed as Schedule I drugs that have “no currently accepted medical use and a high potential for abuse.”

According to the most recent study cited in the Lykos application, more than 86 percent of participants who took MDMA experienced a measurable reduction in the severity of their PTSD symptoms, and 71 percent improved enough that they no longer met the criteria for a diagnosis. Of those who took the placebo, 69 percent improved and nearly 48 percent no longer qualified for a PTSD diagnosis, according to the company’s data.

Perhaps most striking was that the benefits of MDMA therapy endured six months after the final, three-dose regimen, the study found.

“I’d argue that these benefits are better than any psychiatric medication that has been discovered in the history of psychiatry,” said Dr. David Rabin, a neuroscientist and psychiatrist who conducts clinical trials on psychedelic compounds and is not affiliated with Lykos.

But the path toward approval has been bumpy, with advisers to the F.D.A. noting several shortcomings in Lykos’s application and in gaps in the data the company had submitted. The panel, which voted 10 to 1 against the application, cited a number of concerns, including Lykos’s failure to collect detailed data on MDMA’s potential for abuse, its possible cardiac risks and what panelists said were the challenges of standardizing the treatment’s psychotherapy component.

Although not considered a traditional psychedelic, MDMA, or midomafetamine, is a synthetic compound that fosters self-awareness, feelings of empathy and social connectedness.

Should it win F.D.A. approval, federal health authorities and the Justice Department would have to follow certain steps to reclassify the drug to a lower level than the current Schedule I ban, much like the process now underway with cannabis.

The Drug Enforcement Administration could also set production quotas for the drug’s ingredients, as it does with the stimulant medications used to treat ADHD.

The F.D.A. had worked closely with Lykos to develop the clinical trials that evaluated the therapy’s risks and benefits. But the fact that the F.D.A. does not regulate talk therapy has compounded the headwinds facing the company’s application.

Days before the panel vote in June, an independent analysis by the Institute for Clinical and Economic Review, a nonprofit that reviews drugs and their costs, found there was insufficient evidence to determine the overall benefit of MDMA therapy.

Although the advisory panel’s decision is not binding, the agency often follows the recommendations of its experts.

Amy Emerson, the chief executive of Lykos, said the company was confident its application would ultimately secure approval. “We feel the data is really strong, and that none of the concerns that have been raised represent the totality of that patient pool, and they do not negate the overall safety and efficacy findings,” she said.

In rejecting the application, many of the panel’s members said they were concerned about
“functional unblinding,” a problem that affects many studies involving psychoactive compounds because participants may be able to identify whether they have received the drug or the placebo. To reduce the odds of bias skewing the results, those who took part in Lykos’s so-called double-blinded studies were not told whether they had received MDMA or a placebo. But the intensity of the MDMA experience allowed a vast majority to correctly guess which one they had been given.

Dr. Stephen Ross, the associate director of the New York University Langone Health Center for Psychedelic Medicine, said researchers in the field have long struggled to find ways to dampen the effects of functional unblinding. “No one yet has found the holy grail of a placebo that effectively obscures that someone got a drug that creates an unusual experience and does not have therapeutic effects,” he said.

Dr. Maryann Elizabeth Amirshahi, a toxicologist and addiction specialist in Washington, D.C., who served on the F.D.A. advisory panel, said she worried that patients who had a positive experience with MDMA-assisted therapy would seek out illicit forms of the drug, increasing the risk of adverse events. “The last thing you want to do is withhold a promising treatment, but there are just so many unanswered questions in Lykos’ data,” she said in an interview.

Advocates of psychedelic medicine and many experts in the field have been highly critical of the panel’s vote, saying that 10 of the panel’s 11 members had no experience in the field of psychedelics.

“We were shocked because we know the science is there, and after 25 years without new treatments for PTSD, we desperately need this to be approved,” said Marcus Capone, a former Navy SEAL whose organization, Veterans Exploring Treatment Solutions, helps veterans obtain psychedelic therapy at clinics outside the United States.

The F.D.A. could issue a more limited approval requiring Lykos to closely monitor its MDMA-therapy program and report any adverse effects to the agency. It could also require the company to undertake additional studies, a decision that would most likely add years to the approval process. The agency could simply postpone a final decision and ask Lykos to provide additional data. Such a determination, known as a Complete Response Letter, is likely to be confidential.

Postponing approval could cast a chill over the entire field.

“We need the big biotech funds to be investing in psychedelics, and a no vote would validate why many of them have been sitting on the sidelines until now,” said Dustin Robinson, the managing principal of Iter Investments, which focuses on psychedelic companies.

The F.D.A. does not comment on impending decisions, but experts say the political sensitivities surrounding MDMA are especially daunting given the high-profile support from veterans groups. The agency is also undoubtedly mindful of regulatory failures, including criticisms of its own shortcomings, that helped fueled the nation’s opioid crisis.

What no one disputes is the urgent need for new treatments for PTSD. Heroic Hearts Project, an organization that helps veterans obtain psychedelic treatment at clinics outside the United States, has more than 1,000 veterans on a waiting list.

Juliana Mercer, a board member with the organization and a Marine Corps veteran, said she and other supporters worried that the unconventional nature of psychedelic therapies was dampening the application’s prospects at the F.D.A.

“We just want to make sure that the stigma associated with MDMA doesn’t influence their decision,” she said. “It would be a shame for stigma to keep a lifesaving treatment from millions of people.”

ShareTweetSend
Previous Post

This Vaccine Is Tied to a 17% Lower Dementia Risk

Next Post

Dramatic moment Ukraine’s forces smash through Russian border in blow to Putin | World | News

Related News

Discover the Fascinating Secrets of NASA’s Voyager Mission: Test Your Knowledge!
Science

Discover the Fascinating Secrets of NASA’s Voyager Mission: Test Your Knowledge!

November 19, 2026
Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions
Science

Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions

November 18, 2026
Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance
Science

Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance

November 14, 2026
Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse
Science

Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse

November 12, 2026
Next Post
Dramatic moment Ukraine’s forces smash through Russian border in blow to Putin | World | News

Dramatic moment Ukraine's forces smash through Russian border in blow to Putin | World | News

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      Trump Raises Alarm Over Possible Chemical or Biological Weapons Development in Tehran Amid Rising Tensions

      Trump Raises Alarm Over Possible Chemical or Biological Weapons Development in Tehran Amid Rising Tensions

      November 19, 2026
      APC Leader Calls for Unity Among Tinubu and Yari to Strengthen Kano’s Political Landscape in 2027

      APC Leader Calls for Unity Among Tinubu and Yari to Strengthen Kano’s Political Landscape in 2027

      November 19, 2026
      Trump’s Deal Turns Sour as Voters Withdraw Support

      Trump’s Deal Turns Sour as Voters Withdraw Support

      November 19, 2026
      Hong Kong’s Building Maintenance Authority Secures HK3 Million to Expand Operations and Recruit 160 New Employees

      Hong Kong’s Building Maintenance Authority Secures HK$413 Million to Expand Operations and Recruit 160 New Employees

      November 19, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy